Coronary artery diseaseEffects of Atorvastatin on Vitamin D Levels in Patients With Acute Ischemic Heart Disease
Section snippets
Methods and Results
Patients hospitalized for an acute coronary syndrome, defined as high-risk unstable angina, non–ST-elevated myocardial infarction, or ST-elevated myocardial infarction, were eligible for inclusion. Eighty-three patients (52 men and 31 women) with an acute coronary syndrome (75 with acute myocardial infarction and 8 with unstable angina) were included. Patients were recruited at hospital admission. Exclusion criteria were alcoholism, neoplasia, hyper- or hypocalcemia, and treatment with
Discussion
These results show that atorvastatin significantly increased vitamin D levels, thus decreasing the percentage of patients with vitamin D deficiency, a previously unrecorded finding. Comparable findings come from 2 small studies that included 18 patients with familial hypercholesterolemia, which showed that lovastatin and simvastatin treatments resulted in increased plasma levels of vitamin D.4, 5 Grimes6 analyzed analogies between vitamin D and statins and suggested that part of the benefits
References (11)
Vitamin D and disease prevention with special reference to cardiovascular disease
Prog Biophys Mol Biol
(2006)Vitamin D physiology
Prog Biophys Mol Biol
(2006)- et al.
Role of the renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease
Am J Cardiol
(2006) - et al.
Effects of vitamin D3 derivatives on cholesterol synthesis and HMG-CoA reductase activity in cultured cells
J Lipid Res
(1989) Resurrection of vitamin D deficiency and rickets
J Clin Invest
(2006)
Cited by (140)
Vitamin D and cardiovascular diseases
2024, Advances in Food and Nutrition ResearchRelationship between vitamin D and cholesterol levels in STEMI patients undergoing primary percutaneous coronary intervention
2022, Nutrition, Metabolism and Cardiovascular DiseasesThe cholesterol pathway: impact on immunity and cancer
2022, Trends in ImmunologyObesity and dyslipidemia
2019, Metabolism: Clinical and Experimental
This study was supported by Pfizer, Madrid, Spain.